Fondazione G.B.Bietti Per Lo Studio E La Ricerca In Oftalmologia

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions

• Macular degeneration11 trials
• Diabetic eye disease4 trials
• Glaucoma3 trials
• High blood pressure1 trial

Phase

• Phase 312 trials
• Phase 23 trials
• Phase 2/33 trials

Status

• Active, not recruiting6 trials
• Completed5 trials
• Recruiting5 trials
• Not yet recruiting2 trials

Lead sponsor

• AbbVie3 trials
• Eyebiotech Limited2 trials
• Hoffmann-La Roche2 trials
• Annexon, Inc.1 trial
• Bayer1 trial
• and 9 more

Running trials

• Recruiting

  A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

  NCT07705607· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A clinical trial of EYE201/MK-8748 in people with macular degeneration (MK-8748-003)

  2025-524894-17-00· Phase 2/3· Eyebiotech Limited· Source

• Recruiting

  A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

  NCT07441642· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME

  NCT06957080· Phase 2/3· EyeBiotech Ltd.· Source

• Recruiting

  A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

  NCT06659549· Phase 2· Galimedix Therapeutics Inc· Source

• Active, not recruiting

  A randomized study to evaluate the Efficacy and Safety of Intravitreal EYE103 Compared to Anti-VEGF (in patients with Diabetic Macular Edema)

  2024-510944-30-00· Phase 2/3· Eyebiotech Limited· Source

• Recruiting

  A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

  NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)

  NCT06510816· Phase 3· Annexon, Inc.· Source

• Recruiting

  Efficacy of Citicoline Eye Drops 2% on Visual Field Preservation in Patients With Open Angle Glaucoma

  NCT05710198· Phase 3· Omikron Italia S.r.l.· Source

• Active, not recruiting

  Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

  NCT05407636· Phase 3· AbbVie· Source

• Active, not recruiting

  A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

  NCT04657289· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

  NCT03999801· Phase 2· AbbVie· Source

• Recruiting

  Extension Study for the Port Delivery System With Ranibizumab (Portal)

  NCT03683251· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Macular degeneration6 recruiting
• Diabetic eye disease1 recruiting

Closed trials

• Completed

  A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

  2023-507207-66-00· Phase 3· Oculis Operations S.a.r.l.· Source

• Completed

  RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES.

  2023-504759-28-00· Phase 3· Genetic S.p.A.· Source

• Completed

  A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration

  NCT04757636· Phase 3· Opthea Limited· Source

• Completed

  Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

  NCT04423718· Phase 3· Bayer· Source

• Completed

  Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

  NCT03850782· Phase 3· AbbVie· Source